Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV negative youth age 12-17 years (No serologic evidence of HIV infection).~* Negative hepatitis B serology. (No serologic evidence of hepatitis B surface antigen (HBSAg), hepatitis B surface antibody (HBsAb or anti-HBs) and hepatitis B core antibody (HBcAb or anti-HBc)).~* Either no prior hepatitis B immunizations or unknown or incomplete hepatitis B immunization status.~* Willing to participate in HIV risk-reduction counseling and computer assisted measurement of behaviors.~* Parent or legal guardian willing to provide written permission~* Females of childbearing potential must have a negative pregnancy test at screening and should agree to avoid pregnancy through the end of the vaccine phase of the study. Females who are engaging in sexual intercourse must be willing to practice a reliable method of birth control through the end of the vaccine-phase of the study (approximately 6 months). The decision of what is reliable is at the discretion of the site investigator.~Exclusion Criteria:~* Presence of any serious illness requiring treatment with systemic medications, excluding treatment for asthma.~* Previous allergic reaction to any vaccines or to constituents of these vaccines (yeast, thimerosal or aluminum)~* Pregnancy~* Current immunomodulator therapy~* Receipt of immunosuppressor therapy (more than 10 mg/day of prednisone or equivalent for \>1 week) in the 6 months preceding entry or anticipated long-term corticosteroid therapy in the above dose and duration. Short term (\< 7 days) steroid use for the treatment of asthma is not an exclusion.~* Receipt of any vaccine within 2 weeks preceding study entry.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
- 2 (Type: EXPERIMENTAL): Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.

Based on this trial design, predict the completion outcome and termination type (if applicable).